Hepatitis B Vaccine Study in HIV Patients
Author Information
Author(s): Cornejo-Juárez Patricia, Volkow-Fernández Patricia, Escobedo-López Kenia, Vilar-Compte Diana, Ruiz-Palacios Guillermo, Soto-Ramírez Luis Enrique
Primary Institution: Instituto Nacional de Cancerología, Mexico City, México
Hypothesis
Does a higher dose of Hepatitis B vaccine improve seroconversion rates in HIV-infected patients?
Conclusion
Increasing the dose of the HBV vaccine did not improve the response rate in HIV-infected patients, but a CD4 count of 200 cells/mm3 or more was associated with better seroconversion.
Supporting Evidence
- 60.7% of patients in the study seroconverted after vaccination.
- CD4 count ≥ 200 cells/mm3 was significantly associated with higher seroconversion rates.
- No significant difference in seroconversion rates between the two vaccine doses.
Takeaway
The study tested if giving a stronger Hepatitis B vaccine helps people with HIV get better protection, but it turns out the dose doesn't matter as much as having enough healthy immune cells.
Methodology
A double-blind, randomized controlled trial comparing two doses of HBV vaccine (10 μg and 40 μg) in HIV-infected patients with different CD4 counts.
Potential Biases
Potential bias due to the small sample size and loss of follow-up in some patients.
Limitations
The sample size was small, which may limit the ability to detect differences between vaccine doses.
Participant Demographics
HIV-infected patients aged over 16, with a mix of genders and exposure routes.
Statistical Information
P-Value
0.003
Confidence Interval
95% CI = 3.67–35.59
Statistical Significance
p = 0.003
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website